Patients who is scheduled elective PCI are randomized to pitavastatin 4mg daily or without pitavastatin for 5 -7days before the procedure. Creatine kinase-MB, troponin I, and myoglobin levels are measured at baseline and at 8 and 24 hours after the procedure(1st evaluation). After PCI, pitavastatin will be administered for additional 4 weeks(2nd evaluation).
Procedural ischemic myocardial injury remains the most frequent complication after coronary angioplasty. Recently it was reported that pretreatment with atorvastatin reduce the myocardial damage compared to placebo. Thus, we will evaluate the difference of pretreatment of pitavastatin compared to standard therapy on the reduction of myocardial damage in patient who is scheduled elective PCI for stable angina pectoris.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
4mg daily for 5-7 days before Percutaneous Coronary Intervention(PCI) and 4mg daily for 28 days after PCI
4mg daily for 28 days after PCI
Catholic University of Korea Kangnam St. Mary's Hospital
Seoul, South Korea
Proportion of patients whose CK-MB > 2 times above UNL
Time frame: First evaulation time (before PCI)
Proportion of patients who show any increase of CK-MB, troponin I, and myoglobin above UNL
Time frame: First evaluation time
Mean peak values of CK-MB, troponin I and myoglobin after intervention
Time frame: After PCI (<24hrs)
Change of hs-CRP, wall motion score
Time frame: Second evaluation time
Occurence of all major adverse cardiac events
Time frame: Second evaluation time
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.